23R0002_ATNAA_JA_FINAL_Signed_Redacted1.pdf

This document is a Justification for Other Than Full and Open Competition for the Antidote Treatment Nerve Agent Auto-Injector (ATANA) for the Defense Logistics Agency (DLA) Troop Support, Medical Supply Chain. The procurement is for a one-year base contract with four one-year options for a single-source item from Meridian Medical Technologies (MMT), with a National Stock Number of 6505-01-362-7427. The contract specifies a minimum quantity of 225,000 and maximum quantity of 1,000,000 units per year, with pricing details redacted.

The justification emphasizes that ATANA is a dual-chamber injector containing atropine and pralidoxime chloride, used to treat organophosphorus nerve agent poisoning, and is exclusively sold to the United States Military. MMT is currently the only FDA-approved manufacturer of this specific auto-injector. A Sources Sought Notice was issued on June 6, 2023, via SAM.gov seeking alternative sources, which closed on July 5, 2023 with three responses received. The document includes multiple levels of review and approval from DLA Troop Support personnel, culminating in final approval by the Senior Procurement Executive.